Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
Light Chain Bioscience | Novimmune SA
Light Chain Bioscience – A brand of Novimmune SA
We are thrilled to share in our recent article published in mAbs, some structural insights on how antibody light chains can drive antigen binding.
In contrast to natural antibodies that rely mainly on the heavy chain to establish contacts with their cognate antigen, we have developed a bispecific antibody format, called the kappa-lambda body (κλ body), bearing a common heavy chain and two different light chains that drive antigen binding and specificity of each arm of the bispecific antibody.
The structures can be found here :
Importantly, κλ bodies retain truly native human sequences and structure, maximizing their therapeutic potential. Currently three bispecific κλ bodies are undergoing evaluation in Phase I clinical trials.
Light Chains can do it!
#mAbs #CD47 #PD-L1